当前位置: X-MOL 学术Cancer Lett. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Hypoxia-responsive nanoparticles for tumor-targeted drug delivery.
Cancer Letters ( IF 9.7 ) Pub Date : 2020-06-23 , DOI: 10.1016/j.canlet.2020.05.032
Yuce Li 1 , Jueun Jeon 1 , Jae Hyung Park 2
Affiliation  

Hypoxia is a negative prognostic indicator of solid tumors. Increasing evidence indicates that the intratumoral hypoxic microenvironment is strongly related to enhanced tumor aggressiveness, decreased therapeutic effect and poor prognosis of chemotherapy, radiotherapy (RT), and photodynamic therapy (PDT). However, due to an unusual gene expression profile and abnormal metabolism, enzymes responsible for reduction reactions or electron donation are highly reactive in hypoxic tumor cells and provide the possibility of exploiting targeted drug delivery systems for cancer therapy. Taking advantage of the specific bioreductive microenvironments in hypoxic tumors, researchers have recently developed several hypoxia-responsive nanoparticles (HR-NPs) for targeted cancer therapy. In this review, the hypoxia-responsive molecular structures that were employed to construct HR-NPs are presented. Furthermore, the strategies to make use of these HR-NPs, and the recent advances in HR-NPs for efficient tumor-targeted drug delivery and cancer therapy are highlighted.



中文翻译:

低氧反应性纳米颗粒用于靶向肿瘤的药物递送。

低氧是实体瘤的阴性预后指标。越来越多的证据表明,肿瘤内缺氧的微环境与增强的肿瘤侵袭性,降低的治疗效果以及化学疗法,放射疗法(RT)和光动力疗法(PDT)的不良预后密切相关。然而,由于异常的基因表达谱和异常的代谢,负责还原反应或给电子的酶在低氧肿瘤细胞中具有高反应性,并提供了利用靶向药物递送系统进行癌症治疗的可能性。利用缺氧肿瘤中特定的生物还原性微环境,研究人员最近开发了几种针对缺氧反应的纳米颗粒(HR-NP)用于靶向癌症治疗。在这篇评论中 介绍了用于构建HR-NP的低氧反应性分子结构。此外,突出了利用这些HR-NP的策略,以及HR-NP在有效靶向肿瘤的药物递送和癌症治疗方面的最新进展。

更新日期:2020-07-01
down
wechat
bug